戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ntributor to poor prognosis in patients with systemic amyloidosis.
2  familial amyloid polyneuropathy, and senile systemic amyloidosis.
3  a benign course and are not associated with systemic amyloidosis.
4 f familial amyloid polyneuropathy and senile systemic amyloidosis.
5 h gelsolin amyloidosis, an inherited form of systemic amyloidosis.
6 P component (SAP) for potential treatment of systemic amyloidosis.
7 tic use of this antibody in the treatment of systemic amyloidosis.
8 yloidosis) is among the most common forms of systemic amyloidosis.
9  lysozyme, a protein that is associated with systemic amyloidosis.
10 zyme linked with a rare but fatal hereditary systemic amyloidosis.
11  therapeutical approach in the management of systemic amyloidosis.
12 retinal vasculitis, vitreous hemorrhage, and systemic amyloidosis.
13 lin (beta2-m) which is related to hereditary systemic amyloidosis.
14 4, as alternative radiotracers for detecting systemic amyloidosis.
15  but fatal hereditary form of nonneuropathic systemic amyloidosis.
16 e TTR, a condition that characterizes senile systemic amyloidosis.
17 ant D76N causes a very rare form of familial systemic amyloidosis.
18  the Ser131Cys mutation and association with systemic amyloidosis.
19 ourse or outcomes, or risk of progression to systemic amyloidosis.
20 , the pathogenic aggregation of which causes systemic amyloidosis.
21 amily died from renal failure as a result of systemic amyloidosis.
22 on, phase 1 trial involving 15 patients with systemic amyloidosis.
23 ndividuals older than age 65 y causes senile systemic amyloidosis.
24 nts and outcomes of renal transplantation in systemic amyloidosis.
25 new phenotype of late onset fatal hereditary systemic amyloidosis.
26 w cardiac deposition resembling human senile systemic amyloidosis.
27 thy caused by autosomal dominant, hereditary systemic amyloidosis.
28  in amyloid deposits of patients with senile systemic amyloidosis.
29 brils observed in a fatal hereditary form of systemic amyloidosis.
30 1 patients newly diagnosed as having primary systemic amyloidosis.
31  is associated with a fatal familial form of systemic amyloidosis.
32 r conjunctivitis; some patients also develop systemic amyloidosis.
33 rednisone treatment in patients with primary systemic amyloidosis.
34 t) TTR amyloid deposits are linked to senile systemic amyloidosis, a common disease of aging, while s
35 ECT2) to the list of proteins that can cause systemic amyloidosis, a fibrillar protein deposition dis
36 tion of immunoglobulin light chains leads to systemic amyloidosis, a lethal disease characterized by
37 other common age-related comorbidity, senile systemic amyloidosis, a nongenetic disease associated wi
38       beta2-Microglobulin is responsible for systemic amyloidosis affecting patients undergoing long-
39 luated the potential use of (11)C-PIB PET in systemic amyloidosis affecting the heart.
40 (ALECT2), one of the most prevalent forms of systemic amyloidosis affecting the kidney and liver.
41                                      Primary systemic amyloidosis (AL) is a fatal plasma cell disorde
42                                      Primary systemic amyloidosis (AL) is a multisystemic disorder re
43                                      Primary systemic amyloidosis (AL) is a plasma cell (PC) dyscrasi
44                                      Primary systemic amyloidosis (AL) is a plasma cell dyscrasia res
45                                      Primary systemic amyloidosis (AL) is a protein conformation diso
46                                      Primary systemic amyloidosis (AL) is a rare monoclonal plasma ce
47                                      Primary systemic amyloidosis (AL) is an incurable plasma cell di
48                       Cardiac involvement in systemic amyloidosis (AL) occurs in ~50% of all AL patie
49            Multiple myeloma (MM) and primary systemic amyloidosis (AL) remain incurable disorders, an
50  the precursor protein of amyloid in primary systemic amyloidosis (AL).
51 lasma cells (PBPCs) in patients with primary systemic amyloidosis (AL).
52 is being used to treat patients with primary systemic amyloidosis (AL).
53 se process in selected patients with primary systemic amyloidosis (AL); however, SCT for AL remains c
54 misfolded protein aggregates produced during systemic amyloidosis allow for plasma FXIIa and prekalli
55       The amyloid fibril deposits that cause systemic amyloidosis always contain the nonfibrillar nor
56 he tissue amyloid deposits that characterize systemic amyloidosis, Alzheimer's disease and the transm
57 e of precursor protein synthesis, whereas in systemic amyloidosis, amyloid deposition occurs distant
58 n familial amyloid polyneuropathy and senile systemic amyloidosis and appears to be the causative age
59 y provide a new therapeutic approach to both systemic amyloidosis and diseases associated with local
60 asis of heart dysfunction in sporadic senile systemic amyloidosis and familial amyloid cardiomyopathy
61 ave been described for transthyretin (senile systemic amyloidosis and familial amyloid polyneuropathy
62 amyloid fibrils that putatively cause senile systemic amyloidosis and familial amyloid polyneuropathy
63 l formation and possibly the diseases senile systemic amyloidosis and familial amyloid polyneuropathy
64 posplenism may be a marker of more extensive systemic amyloidosis and has been correlated to a reduct
65                            All patients with systemic amyloidosis and heart failure referred for hear
66                  A total of 25 patients with systemic amyloidosis and heart failure were included in
67 ry amyloidosis, familial amyloidosis, senile systemic amyloidosis, and localized amyloidosis were exc
68 ransthyretin (TTR) is responsible for senile systemic amyloidosis, and more than 100 mutations in the
69                           Many patients with systemic amyloidosis are underdiagnosed.
70 onset and development of disorders including systemic amyloidosis, as well as the neurodegenerative c
71      A 57-year-old Irish man with hereditary systemic amyloidosis associated with apoAI Gly26Arg, whi
72 thought to be the second most common form of systemic amyloidosis behind amyloidosis secondary to mon
73 isplayed shortened survival characterized by systemic amyloidosis but no evidence of excessive cellul
74 osis (AL) is one of the most common types of systemic amyloidosis but there is no reliable in vivo mo
75                                              Systemic amyloidosis caused by extracellular deposition
76                                   Hereditary systemic amyloidosis caused by fibrinogen Aalpha-chain g
77 ifferent forms of hereditary non-neuropathic systemic amyloidosis, caused, respectively, by Leu60Arg
78 r AL) amyloidosis is the most common form of systemic amyloidosis, characterized by the pathological
79 e or cardiomyopathy within 2 years after the systemic amyloidosis code.
80                                              Systemic amyloidosis complicated by heart failure is ass
81                                 Treatment of systemic amyloidosis comprises measures to support faili
82  amyloid deposits in patients diagnosed with systemic amyloidosis could be visualized with (11)C-PIB.
83 MWCs) in serum samples from individuals with systemic amyloidosis due to aggregation and deposition o
84 ntation remains contentious in patients with systemic amyloidosis due to the risk of graft loss from
85                                              Systemic amyloidosis encompasses a debilitating, under-d
86 sociated with three amyloid diseases: senile systemic amyloidosis, familial amyloid polyneuropathy, a
87 quaternary structures associated with senile systemic amyloidosis, familial amyloid polyneuropathy, a
88  Mutations in gelsolin are responsible for a systemic amyloidosis first described in 1969.
89                                              Systemic amyloidosis from transthyretin (ATTR) protein i
90 ulmonary amyloidosis associated with primary systemic amyloidosis generally presents as a diffuse int
91 hat D18G does not lead to severe early onset systemic amyloidosis, given that it is the most destabil
92                                      Primary systemic amyloidosis has been associated with the develo
93 eta2-microglobulin, D76N, causing hereditary systemic amyloidosis, have become particularly relevant
94 ysozyme, which are associated with a form of systemic amyloidosis, have been investigated by a wide r
95 cognized as one of the most common causes of systemic amyloidosis in North America.
96 essive, highly penetrant, autosomal-dominant systemic amyloidosis in persons heterozygous for the cau
97 myloids and are linked to the development of systemic amyloidosis in vivo.
98             Patients (n = 10) diagnosed with systemic amyloidosis-including heart involvement of eith
99                                              Systemic amyloidosis involves the deposition of misfolde
100                                              Systemic amyloidosis is a fatal disease caused by misfol
101                                      Primary systemic amyloidosis is an immunoglobulin deposition dis
102                                      Primary systemic amyloidosis is an uncommon disease characterize
103                              Non-neuropathic systemic amyloidosis is associated with single point mut
104                                              Systemic amyloidosis is caused by misfolding and aggrega
105                                              Systemic amyloidosis is characterized by amyloid deposit
106      Heart transplantation for patients with systemic amyloidosis is controversial due to recurrence
107                        Accurate diagnosis of systemic amyloidosis is necessary both for assessing the
108                                   Hereditary systemic amyloidosis may be caused by mutations in a num
109 (11)C-PIB and PET could be a method to study systemic amyloidosis of type AL and ATTR affecting the h
110 tin causes the human amyloid diseases senile systemic amyloidosis or familial amyloid polyneuropathy,
111 e potential to modulate the course of senile systemic amyloidosis or familial amyloid polyneuropathy.
112 ment in patients with amyloidosis is common, systemic amyloidosis presenting with angina is rare.
113  and life-saving treatment for patients with systemic amyloidosis relies on the astute clinician reco
114                                              Systemic amyloidosis results from the deposition of inso
115 ing localized pulmonary amyloidosis, primary systemic amyloidosis, secondary amyloidosis, and familia
116                                       Senile systemic amyloidosis (SSA) is one such pathology and fea
117                                       Senile systemic amyloidosis (SSA), however, cannot be explained
118  familial TTR-related amyloidosis and senile systemic amyloidosis (SSA), TTR is deposited as amyloid
119 eposition of wild-type transthyretin (senile systemic amyloidosis, SSA) or monoclonal immunoglobulin
120                        Patients with primary systemic amyloidosis that affects the heart have a poor
121 erived chemotaxin 2 (LECT2) causes ALECT2, a systemic amyloidosis that affects the kidney and liver.
122 ients with pulmonary amyloidosis had primary systemic amyloidosis that presented radiographically as
123 tabolic disorders (eg, type 2 diabetes), and systemic amyloidosis, the association between Agent Oran
124  months and 4 years in whom the diagnosis of systemic amyloidosis was unsuspected before or until jus
125 ontribute to effective treatment not only of systemic amyloidosis, which is relatively rare, but also
126 in the viscera and connective tissues causes systemic amyloidosis, which is responsible for about one
127 London, between 2015 and 2017 with suspected systemic amyloidosis who underwent SAP scintigraphy and
128      Our purpose is to present a new case of systemic amyloidosis with a bilateral conjunctival invol
129                  beta(2)m-D76N causes a rare systemic amyloidosis with protein deposited in the visce
130                                              Systemic amyloidosis, with amyloid deposits in the visce

 
Page Top